NEW YORK (GenomeWeb News) – Molecular diagnostics developer VitaPath Genetics has raised $6 million in a private equity financing that was led by MDV-Mohr Davidow Ventures and included an investment from X/Seed Capital.

The company is developing a genetic test for spina bifida, a birth defect that affects the spine and which can be avoided with high doses of folic acid therapy.

The company plans to use the Series A financing to complete the validation of this first assay and to prepare for its commercial launch.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.

Bill Gates tells the Telegraph that bioterrorism is a serious risk.

The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.

CBS News reports that the White House Science Fair is to continue under President Donald Trump.